GlassScriptPhysician profile
Kathlene Rasmussen
NPI 1245808526
$3,165.10
in general payments reported to CMS, 2019-2025
19 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,554 · 2024: $452 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650 · Travel and Lodging: $1,218 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,649.86 |
| Travel and Lodging | $1,217.92 |
| Education | $297.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $1,837.98 | 2023 | |
| Exelixis INC. | $206.86 | 2024 | Cabometyx |
| Janssen Biotech, INC. | $138.92 | 2023-2024 | Carvykti, Tecvayli, Darzalex |
| Eisai INC. | $138.85 | 2023-2024 | |
| Abbvie INC. | $128.69 | 2023-2024 | |
| Lilly USA, LLC | $116.42 | 2023 | Jaypirca, Retevmo, Verzenio |
| Pfizer INC. | $114.61 | 2024 | |
| Adc Therapeutics America, INC. | $110.96 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $87.95 | 2023 | Imfinzi |
| Neurocrine Biosciences, INC. | $55.44 | 2023 | |
| Pharmaessentia USA Corporation | $44.21 | 2025 | Besremi |
| Genentech USA, INC. | $41.05 | 2025 | Columvi, Tecentriq |
| Immunocore Limited | $32.80 | 2024 | Kimmtrak |
| Blueprint Medicines Corporation | $23.90 | 2025 | Ayvakit |
| Astellas Pharma Global Development | $21.30 | 2025 | Vyloy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19.47 | 2024 | Reblozyl |
| Novocure INC. | $17.47 | 2025 | Optune Lua (Novottf-200t) |
| Kyowa Kirin, INC. | $16.75 | 2024 | Poteligeo |
| Iovance Biotherapeutics, INC. | $11.47 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathlene Rasmussen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.